Superworth

Rigel Pharmaceuticals PE ratio RIGL

Share price divided by earnings per share over the last twelve months, since 2024.

Today, Oct 23, 2026
n/m
not a meaningful number
Last meaningful
5.6×
Feb 2026
Peer median
10.8×

Rigel Pharmaceuticals' PE ratio is not a meaningful number today: net income over the last twelve months was more than twice operating income, so most of it came from below the operating line (a gain on a sale, debt written off, a tax benefit, investment income) and the low PE on it says nothing about the business.

It was last meaningful in Feb 2026, at 5.6×.

PE ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far5.6×5.5×6.8×
20257.1×5.2×165×
2024118×118×197×

Against its peers

Companies in Drug Manufacturers - General nearest Rigel Pharmaceuticals' size, closest first, today.

CompanyPE ratio
RIGLRigel Pharmaceuticalsn/m
ABUSArbutus Biopharma5.4×
AMPHAmphastar Pharmaceuticals14.8×
COLLCollegium Pharmaceutical18.5×
OMEROmeros10.9×
CRMDCorMedix3.7×
ZVRAZevra Therapeutics10.5×
IRWDIronwood Pharmaceuticals4.5×
PBYIPuma Biotechnology21.2×
PCRXPacira BioSciences104×
ANABAnaptysbio10.7×
Peer median10.8×

What the PE ratio tells you

Share price divided by earnings per share over the last twelve months. It is the price tag on a dollar of profit: 20× means you pay $20 for $1 of yearly earnings.

Blank while earnings are negative. A very low PE can mean the market expects profits to fall, so read it with growth and the company's own history.

More on Rigel Pharmaceuticals

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.